Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care

Minna A. Korolainen, Samu Kurki, Mariann I. Lassenius, Iiro Toppila, Madlaina Costa-Scharplatz, Timo Purmonen and Markku Nissila

Abstract

Background: The highest prevalence of migraine is detected among people who are of working age. The aim of this study was to assess the burden of migraine in an occupational health care setting using real world data collected as a part of routine clinical practice.

Methods: This retrospective register study included migraineurs using occupational health care at the private health care provider Terveystalo. An age and gender matched control population was established for comparison. Electronic medical records were assessed for overall and migraine related health care visits, sick-leaves and comorbidities. Stratification to acute and prophylactic treatment groups along with prophylactic treatment lines was based on prescriptions.

Results: Among the 369,383 individuals in the study cohort, 7.4% women and 2.1% men were identified having a diagnosis of migraine. Prophylactic medication was prescribed to 13% of migraine patients and exclusively acute medication to 37%. Although migraine related visits and sick-leave days were significantly lower than overall visits or sick-leave days, both increased by prophylactic treatment line. The number of visits rose from 13.8 to 26.2 and sick-leave days from 16.8 to 30.4 per patient-year, in those without prophylaxis vs. ≥3 prophylactic treatments. Moreover, migraine patients had 1.7-fold increase in visits and 1.8-fold increase in sick leave days on average per patient-year, when compared to the control population. Depression and anxiety were 1.8-fold more common among patients with migraine, and the frequency also increase by treatment line.

Conclusions: Migraine burden increased by each failed treatment line and was associated with increased comorbidity. In addition, migraine patients had significantly higher extent of visits and sick-leave days as well as extent of comorbidities when compared to their age- and gender-matched counterparts.

Keywords: Migraine, Comorbidities, Prophylactic treatment, Treatment lines, Absenteeism, Disease burden

Introduction

Migraine has a significant and debilitating impact on physical, social, and occupational functioning. In 2016, it was ranked the first cause of disability worldwide in both men and women under the age of 50 years highlighting the lack of effective disease management [1, 2].

Migraine is classified into episodic (EM) or chronic (CM) according to monthly migraine days. However, this classification is not unambiguous, and fluctuations between the two categories are evident from longitudinal studies [3]. Regardless of monthly migraine days, chronification of migraine is associated with substantially increasing individual and social burden. The burden of migraine has been elucidated in multiple surveys and studies [4–12] and recently Silberstein et al. showed that disease disability, health care resource use (HCRU), and direct costs increase concomitantly with increasing number of headache days [13]. Moreover, it has been established that the migraine burden builds up by increasing number of additional comorbidities such as psychiatric disorders, medication overuse, obesity, and respiratory and cardiovascular diseases [14–17]. It is
known that e.g. depression and anxiety, as comorbidities among migraine patients, increase both direct and indirect costs [16, 18, 19].

Migraine is variably managed with acute (anti-inflammatory analgesics and triptans) and if needed with prophylactic (beta-blockers, tricyclics, candesartan and antiepileptics) treatment options [16, 20]. None of the current prophylactic treatments have originally been developed for migraine, and their specific mechanisms of action in migraine are not known. In a systematic review, adverse events were identified as the most common reason for treatment discontinuation [21]. In another study, up to 88% on prophylactic treatment reported lack of efficacy as the reason for treatment switch [22]. It is evident that adherence and persistence to current migraine prophylaxis is not optimal. The attention has recently thus turned into revealing the true impact of migraine disease burden also for patients in the need or failing prophylactic treatments [5, 23].

Several surveys and studies have been conducted on the burden of migraine, and some of them also using data from Finland [4, 24, 25]. However, studies on large register based data collected as part of clinical routine care are lacking. The main aim of the present study was to examine the burden of migraine and evaluate HCRU, sick-leaves and comorbidities among migraine patients compared to a control population in occupational health care setting.

**Methods**

Electronic medical records (EMR) of a private health care provider Terveystalo were utilized in this retrospective register-based study. Patients who had given a written informed consent using occupational health care at Terveystalo ($N = 369,383$) were included (Fig. 1). The EMRs included diagnoses, visits, procedures, prescriptions, laboratory measures, and demographical characteristics. The data available covers outpatient care. Altogether, 17,623 of the patients had migraine according to ICD-10 code (G43*, on a three-character level) and were included in the primary cohort. All more detailed ICD-10 codes e.g. G43.5 were included to the three-character G43* level. To assess plausibly misdiagnosed migraine, patients were further included to an extended cohort based one of the following criteria: inclusion to the primary cohort (G43*) or a prescription with the word migraine in the drug prescription text, or prescribed triptan medication ($N = 23,339$, Fig. 1).

The inclusion period to the study and for the follow-up of patients started 1st Jan 2012 and ended 31st December

---

**Fig. 1** Study cohort formation
2017. Each patient was followed from the first G43* diagnosis in the EMR, or from the first fulfilment for any of the criteria for the extended cohort, until 31st December 2017.

Patients in the primary cohort were divided into groups based on medication prescribed at the health care provider. The following ATC classes were considered acute: M01–N02BE, N02CA, N02CC, A03FA, A04AA01, H02AB; and prophylactic: C07–09, N03, N06, G02–03, M03AX01 treatments. For both acute and prophylactic prescriptions, the migraine word in the free text of the prescription was required, since the same drugs can be prescribed for other illnesses as well. The division of patients to acute and prophylactic groups was validated by a neurologist. Botulinum toxin A is only indicated for CM in Finland, and these patients represent a confirmed CM population.

Controls
A one-to-one, age and gender matched control population without migraine was created. For each migraine patient a control patient was randomly chosen based on gender and birth date from the database. No subjects were chosen twice for the control group (controls: N = 17,623, 76,804 patient-years, average age 38.9 years, 78.9% female; Primary cohort: N = 17,623, 51,396 patient-years, average age 38.9 years, 78.9% female). Controls were used as reference for comorbidity estimations, overall sick leaves and visits.

Prevalence
In the health care provider’s register on 31st December 2017, the point prevalence for migraine was calculated by gender in 5-year age groups in the primary and extended cohorts. The consented occupational health care population was used as denominator for the calculation of prevalence.

Treatment lines
A new treatment line was defined as a new unique prophylactic prescription in the health care provider’s register. Treatment lines were assessed for those with prophylactic prescriptions (later referred to as treatment lines). In addition to the word migraine in the free text of the prescription, a G43* diagnosis was required for the analyses. For a full list of prophylactic treatment lines see Appendix 1. For a list of acute migraine medication, see Appendix 2.

Health care resource utilization and sick leave days
Health care resource utilization (HCRU) consisted of both total as well as disease specific visits, and these were tracked separately. For disease specific visits G43* was required as a diagnosis for the visit. All-cause and migraine related values present the minimum and maximum of the HCRU in migraine patients, and most likely the true disease-related HCRU is somewhere in between. All HCRU data is presented as the absolute value, per patient (cumulative number of events/number of patients), and per patient-year (cumulative number of events/cumulative follow-up). Hence, data in patient-years is adjusted for differences in follow-up, that otherwise would bias those with long follow-up to likely have more HCRU.

Quartiles of HCRU and sick leaves
To assess the impact of migraine in subjects with high HCRU, migraine patients were divided into quartiles based on either overall visits or sick-leaves in patient-years. For each patient, the total number of visits and sick-leave days were defined and divided by the total patient-wise follow-up time, where after the cohort was divided into quartiles. Patients with less than 6 months of follow-up were excluded from these analyses. Patients in each quartile were characterized as previously, and the corresponding cut-off values for per patient-year estimate for visits and sick leave days were reported.

Comorbidities
The frequency of comorbidities was assessed at the end of follow-up from ICD-10 codes, in the subgroups and per prophylactic treatment line. Of special interest were depression (F32 single episode, F33 recurrent) and anxiety (F41). The other comorbidities were selected based on highest frequency in the data. A table of the frequency of comorbidities in controls and the primary cohort is presented in Appendix 3.

Statistical methods
For categorical variables Chi square test was used to test for differences in frequencies (quartiles and comorbidities). For continuous variables (age, HCRU, and follow-up time) Kruskal Wallis test was used to evaluate differences between groups. Otherwise data is descriptive in nature.

Results
In the 369,383 individuals with occupational health care data, the overall migraine prevalence was 4.8% in the primary cohort and 6.3% in the extended cohort. Migraine was more frequent in females vs. males (7.4% vs. 2.1%) in the primary cohort, and 9.7% vs. 2.8% correspondingly in the extended cohort. The prevalence of migraine increased between the age of 15 and 20 stabilizing at 8–9% in females and 2.5% in males of the primary cohort and at 10–13% in females and 3.5% in males of the extended cohort in those between 25 and 44 years (Fig. 2). The median age for the first migraine code was 39 years, and 79% of migraineurs were female (Table 1).
Migraine with aura was the most common migraine sub-diagnosis code in 2526 persons (14.3%) of the primary cohort.

Treatments
Only acute migraine drugs were prescribed to 6525 (37%) patients, and at least one prophylactic prescription to 2199 (13%) patients. Moreover, 8899 (51%) individuals with migraine, lacked migraine-related prescriptions in the register (Fig. 1).

Treatment lines were assessed among those with prophylactic prescriptions (Fig. 1). Ninety-eight migraineurs had three or more prophylactic prescriptions, and 53 persons were on botulinum toxin treatment. Patients on prophylaxis were on average 2 years older than those without prophylaxis and the proportion of female gender increased by treatment line (Table 1).

The most common first line prophylactic prescriptions were candesartan (27.4%), followed by amitriptyline (22.1%) and the beta-blockers (cumulative prevalence 27.4%: bisoprolol, propranolol and metoprolol). Second line prophylactic treatments echoed in frequency those of the first line, however topiramate (1st vs. 2nd line: 3.7 vs. 8.1%), nortriptyline (3.6 vs. 6.3%) and nebivolol (1.7 vs. 2.8%) prescriptions were increased (Appendix 1).

Health care resource utilization and sick leave days
Migraine specific and all-cause visits as well as sick leave days were assessed. Patients from the primary cohort with a prophylactic migraine prescription had more visits than those with acute prescriptions or no prescriptions (Table 2, Fig. 3). This was reflected both in total visits (prophylactic vs. acute vs. no prescription: 18.4 vs. 15.0 vs. 12.9 visits per patient-year, \( p < 0.001 \)) and migraine specific visits (2.4 vs. 1.3 vs. 0.8 per patient-year, \( p < 0.001 \)), as well as in total sick leave days (22.5 vs. 17.4 vs. 16.4 per patient-year, \( p < 0.001 \)) and migraine specific sick leave days (2.1 vs. 0.7 vs. 0.5 per patient-year, \( p < 0.001 \)), (Table 2 and Fig. 3). Notably, overall visits in the control population compared to the primary cohort were 8.5 vs. 14.4 (\( p < 0.001 \)) and overall sick leave days 9.7 vs. 17.6 (\( p < 0.001 \)) per patient-year (Table 2).

Botulinum toxin A treatment was associated with 7.8 times more migraine related visits compared to the rest of the primary cohort (\( p < 0.001 \), Table 2). Also, a 2.1-fold increase in migraine related sick leave days was found in subject with botulinum toxin prescriptions. Notably, these persons were annually on sick leave 37 days per patient-year and visited the health care provider every twelfth day (31 times per patient-year), indicating an increase in total morbidity associated with chronic migraine treated with botulinum toxin A (Table 2).

An increase in prophylactic treatment lines was associated with an increase in overall visits (no prophylactic prescriptions, vs. ≥3 prophylactic treatments: 13.8 vs. 26.2 visits per patient-year) as well as disease specific visits (no prophylactic prescriptions vs. ≥3 prophylactic treatments: 1.0 vs. 6.0 visits per patient-year), Table 2 and Fig. 3. A comparable increase in sick-leave days was observed: overall sick leave days (no prophylactic prescriptions, vs. ≥3 prophylactic treatments: 16.8 vs. 30.4 sick leave days per patient-year) and disease specific sick leave days (no prophylactic prescriptions, vs. ≥3 prophylactic treatments: 0.6 vs. 6.7 per patient-year). Sick leave periods followed the same pattern (Table 2).
To explore the impact of migraine on overall visits and sick leave days, patients were stratified to quartiles. A shift in prescriptions towards prophylaxis and an increase in prophylactic treatment lines was associated with an increase in overall visits. Notably, of those with >19.8 visits per patient-year (q4), 20% were on prophylaxis compared to 7.3% of those with less than 7.0 visits per patient-year (q1, Appendix 4). Overall sick-leave days showed a similar increase of prophylactic medication increasing by each quartile of sick-leave days. In those with >19.9 sick-leave days per patient-year (q4), 16% of patients were on prophylaxis, whereas in patients with less than 1.9 sick-leave days per patient-year (q1) 11% were on prophylaxis (Appendix 5).

Comorbidities

Those with prophylactic prescriptions had a 1.4-fold increase in the frequency of depression compared to migraineurs with acute prescriptions (F32: 12.5% vs. 17.1%, p < 0.001; F33: 4.2% vs. 5.9%, p < 0.05). Similarly, 1.3-fold increase of anxiety (F41: 16.8% vs. 18.8%, p < 0.001), and 1.2-fold increase in sleep disorders (F51) was observed in patients on prophylaxis (Fig. 4). In the controls these comorbidities were less frequent, 7% had a single episode of depression (F32), 2% recurrent depression (F33), 8% anxiety (F41), and 8.8% sleep disorders (F51) (Fig. 4). Notably, all comorbidities were 1.4–2.0-fold more frequent in migraine patients compared to controls and the difference was more pronounced in those with prophylactic prescriptions (Fig. 4).

There was a positive association between treatment lines and the frequency of comorbidities. Among migraineurs with prophylactic prescriptions, single episode depression (F32) increased in those with no prophylactic prescriptions vs. 3rd prophylactic treatment line from 12.4% to 30.6%; depression recurrent episodes (F33) from 4.6% to 28.6%; and anxiety (F41) from 13.6% to 28.6%, see Fig. 4. A similar trend was also observed for other comorbidities.

Discussion

In this extensive registry-based retrospective study using EMRs of Finland’s largest private occupational health care provider, 17,623 migraine patients with G43-diagnosis were identified. In this data migraine was associated with substantial morbidity evident as increased comorbidities, as well as increased health care visits and sick leave days when compared to controls. The burden of disease also increased with each additional prophylactic treatment line. The results are aligned with previous studies investigating migraine and indicate that the burden of migraine can be detected in EMRs collected as a part of routine clinical practice.

Treatment unresponsive or refractory migraine, detected as increased numbers of prescribed prophylactic treatments, was associated with up to 3.1-fold increase in all-cause sick leaves and visits compared to controls. Migraineurs on prophylactic treatment were on average on sick leave 22 days annually whereas patients on botulinum toxin A for an average of 37 days annually. The corresponding number of sick-leave days was only ten
for the control group, highlighting the increased burden associated with migraine, as lack of migraine was the main difference between these groups. The reason for prophylactic medication switches may in addition to treatment unresponsiveness have been caused by adverse events. The possibility of add-on therapies due to lack of efficacy can neither be excluded.

Directly migraine-related visits and official sick-leave days only present a minor part of true disease burden and are in line with previous findings. In the Eurolight study, the annual per person cost of migraine-related absenteeism was 371 € [26], which would correspond to approximately 2 days of sick leave in Finland. Similar annual migraine related absenteeism days were found in a longitudinal survey in the US [27]. In our study, botulinum toxin treatment was associated with 11.9 migraine related sick-leave days per patient-year, also in line with approximately 10 days previously reported [27]. However, the effect of prophylactic treatment lines on disease burden has been poorly investigated and the incremental increase of all-cause sick-leaves and visits per additional prophylactic treatment line, underlines that migraine related disease burden cannot solely be assessed by migraine related visits or sick-leaves, but should be considered in a larger perspective. Moreover, this study also investigated the migraine burden per se compared to age and gender matched controls, where all-cause sick-leaves were 1.8 and visits 1.7 more frequent in the migraine population than in the controls per patient-year.

The increase in comorbidities for migraine patients when compared to controls highlights an increased morbidity in this group. This was further supported by the positive correlation of treatments lines and frequency of comorbidities. In patients with 3 or more prophylactic treatments, a mental disorder such as major depressive disorder or anxiety,

Table 2 Total and disease specific visits and sick-leave days of migraine patients and controls

| HCRU and sick leaves | Control | G43*, prim. cohort | G43*, primary cohort |
|----------------------|---------|--------------------|----------------------|
|                      | N       | Patient-years      | Average follow-up time per patient (years) |
|                      | 17,623  | 17,623            | 4.4                  |
|                      | 76,804  | 51,397            | 4.8                  |
|                      | 7,936   | 7,936             | 4.6                  |
|                      | 51,397  | 51,397            | 4.8                  |
|                      | 649,362 | 649,362           | 4.4                  |
|                      | 51,397  | 51,397            | 4.8                  |
|                      | 8,5     | 8,5               | 4.4                  |
|                      | 36.9    | 36.9              | 4.4                  |
|                      | 3.4     | 3.4               | 4.4                  |
|                      | 1.2     | 1.2               | 4.4                  |
|                      | 742,162 | 742,162           | 4.4                  |
|                      | 59,937  | 59,937            | 4.4                  |
|                      | 9.7     | 9.7               | 4.4                  |
|                      | 4.0     | 4.0               | 4.4                  |
|                      | 0.8     | 0.8               | 4.4                  |
|                      | 0.5     | 0.5               | 4.4                  |
|                      | 0.5     | 0.5               | 4.4                  |
|                      | 0.2     | 0.2               | 4.4                  |

|                      | visits  |
|----------------------|---------|
|                      | 649,362 | 649,362           | 4.4                  |
|                      | 59,937  | 59,937            | 4.4                  |
|                      | 4.7     | 4.7               | 4.4                  |
|                      | 4.7     | 4.7               | 4.4                  |
|                      | 4.7     | 4.7               | 4.4                  |
|                      | 4.7     | 4.7               | 4.4                  |
|                      | 4.7     | 4.7               | 4.4                  |
|                      | 4.7     | 4.7               | 4.4                  |

|                      | G43* visits |
|----------------------|-------------|
|                      | total       | 649,362           | 4.4                  |
|                      | per patient | 36.9              | 4.4                  |
|                      | per patient-year | 8.5        | 4.4                  |
|                      | total       | 59,937            | 4.4                  |
|                      | per patient | 3.4               | 4.4                  |
|                      | per patient-year | 1.2        | 4.4                  |
|                      | total       | 742,162           | 4.4                  |
|                      | per patient | 4.7               | 4.4                  |
|                      | per patient-year | 4.7        | 4.4                  |

|                      | G43* sick leave days |
|----------------------|----------------------|
|                      | total                | 649,362           | 4.4                  |
|                      | per patient          | 36.9              | 4.4                  |
|                      | per patient-year     | 8.5               | 4.4                  |
|                      | total                | 59,937            | 4.4                  |
|                      | per patient          | 3.4               | 4.4                  |
|                      | per patient-year     | 1.2               | 4.4                  |
|                      | total                | 742,162           | 4.4                  |
|                      | per patient          | 4.7               | 4.4                  |
|                      | per patient-year     | 4.7               | 4.4                  |

|                      | Sick leave periods |
|----------------------|--------------------|
|                      | total              | 649,362           | 4.4                  |
|                      | per patient        | 36.9              | 4.4                  |
|                      | per patient-year   | 8.5               | 4.4                  |
|                      | total              | 59,937            | 4.4                  |
|                      | per patient        | 3.4               | 4.4                  |
|                      | per patient-year   | 1.2               | 4.4                  |
|                      | total              | 742,162           | 4.4                  |
|                      | per patient        | 4.7               | 4.4                  |
|                      | per patient-year   | 4.7               | 4.4                  |

|                      | G43 sick leave periods |
|----------------------|------------------------|
|                      | total                 | 649,362           | 4.4                  |
|                      | per patient           | 36.9              | 4.4                  |
|                      | per patient-year      | 8.5               | 4.4                  |
|                      | total                 | 59,937            | 4.4                  |
|                      | per patient           | 3.4               | 4.4                  |
|                      | per patient-year      | 1.2               | 4.4                  |
|                      | total                 | 742,162           | 4.4                  |
|                      | per patient           | 4.7               | 4.4                  |
|                      | per patient-year      | 4.7               | 4.4                  |

BT botulinum toxin; Significance indicated between 1: controls and G43* primary cohort; 2: prophylactic, acute and no migraine prescription groups; 3: Botulinum toxin treated and untreated patients; 4: between prophylactic treatment lines
*p < 0.001
was diagnosed in every third person. This contrasts with controls where depression was diagnosed in every 14th (7%) person and anxiety in every 13th (8%) person.

The previously reported frequency of comorbidities varies partly because of methodological aspects. In chronic migraine up to 57% of patients were detected to have major depression and 8% anxiety when screened in a clinic-based study [28]. Also, an increase of prophylactic medication in subjects with migraine and depression, compared to migraine alone, has been described even though prophylactic treatment lines were not assessed [29]. Depression and migraine are bidirectionally associated, with both illnesses adding to the risk of developing the other [30]. Common neurological etiology is also shared between migraine, depression and sleep disorders [31], which in addition to reaction to severe stress and dorsopathies, were more frequent in patients with migraine compared to controls.

Migraine has been one of the top five leading causes for years lived with disability (YLD) globally since 1990, highlighting the unmet need of more effective migraine management [2]. This was also seen in our study in the concomitant increase between prophylactic treatment lines and absenteeism, visits as well as comorbidity. Multimorbidity is known to influence the overall disease burden due
to polypharmacy, reduced quality of life, increased disability and mortality as well as increased HCRU. Multimorbidity is thought to include 2–3 or more simultaneous conditions and has been described in chronic migraine [32]. The higher frequency of depression and anxiety, accompanied by the seven most common comorbidities in migraine patients in the study, points at the possibility of notable existence of multimorbidity also in less severe migraine patients. Moreover, efficient treatment of migraine including psychiatric comorbidities such as depression is considered essential in avoiding migraine chronification [14].

Fig. 4  a The frequency of comorbidities in controls (white) and patients with migraine (G43*) according to prescriptions of migraine medications [no prescription (light grey), acute (dark grey), prophylactic prescriptions (black)]. Significance is indicated between controls and migraine patients, as well as between migraine groups. b Comorbidities by prophylactic treatment line [no prophylactic prescriptions (white); 1st prophylactic treatment line (light grey); 2nd prophylactic treatment line (dark grey); 3rd or more treatment line (black)]. Significance is indicated between four groups. *p < 0.001; †p < 0.005. F32 – depression single episode; F33 – depression recurrent; F41 – anxiety; F43 – stress reaction; F51 – sleep disorder; J01 – sinusitis; J06 – upper respiratory infections; J20 – bronchitis; M53 – dorsopathy; M54 dorsalgia

Diagnosing people with migraine is important in the light of making optimal treatment decisions and to positively influence the disease burden. According to previous mostly survey-based prevalence studies, about 9.6–15% among the general population suffer from migraine [25, 33–35]. Therefore, the total migraine prevalence of 4.8–6.3% among people in occupational health care reported here would seem very conservative, especially when considering the well-known age-dependence in migraine prevalence [36]. However, it must be noted that the prevalence has been extracted from EMRs, collected as a part of routine clinical care plausibly explaining the lower numbers [37].
senteeism is only responsible for one third of migraine-related indirect costs and presenteeism is thought to account for the rest two thirds [26]. Estimations of presenteeism were not included in this study. Further studies are warranted to elucidate whether self-notice absenteeism and presenteeism correlate with the increased disease burden detected here.

Strengths of the study were that data was gathered in a real-world setting without strict inclusion/exclusion criteria, and the ability to put the disease burden into perspective when compared to those not suffering from migraine. The study included EMRs of the Finland’s largest private occupational health care provider having more than 150 clinics across the country. As occupational health care must be provided by the employer according to the Finnish law, there is also no selection of members due to societal status or position from the health care provider. Further, the study examined true clinical data and is not claims based. As headache diaries are not included in EMRs, the lack of successful migraine management and more severe disease was estimated through history of one or more prophylactic treatment failures for migraine prevention.

The study uniquely combines prescriptions, comorbidities and absenteeism in patients able to work and controls to assess the impact of failed treatments on increasing disease burden. It is possible that failed treatments leading to increased disease burden may reflect chronicification of migraine. Another interesting aspect in the future would be to evaluate the impact of successful migraine prevention on disease burden. There has been at least one study showing a potential concomitant positive influence on depression and anxiety when chronic migraine was treated with botulinum toxin A [17, 41].

Conclusions
This study provided new evidence on the disease burden of migraine from EMRs collected as a part of routine clinical care in Finland and complements the extensive evidence mostly from survey-based studies. In this study, migraine patients show a substantially higher extent of comorbidities, sick-leave days and health care visits compared to their age- and gender-matched counterparts. Moreover, the increased disease burden was not directly linked to G43-diagnosis but was rather detected via other diagnostic codes potentially reflecting other migraine-related comorbidity. This study highlights the need to more effectively manage migraine to avoid detrimental effects on health and quality of life that are associated with treatment unresponsive or undertreated migraine. Unresponsive or undertreated migraine, evidenced by an increase in failed treatment lines, increases morbidity and inevitably leads to productivity losses that pose an increased burden on the health care system and society.
Table 3 Prophylactic treatment lines of patients with G43*diagnosis and the word migraine in the free text of a prophylactic migraine prescription. A new treatment line was defined as a new drug prescription

| ATC     | Drug name                          | Prescr, by neurologist (%) |
|---------|------------------------------------|----------------------------|
|         |                                     | 1 (%) | 2 (%) | 3 (%) | 4 (%) | 5 (%) | 6 (%) | 7 (%) |
| C09CA06 | Candesartan                         | 27.38  | 23.61  | 21.43  | 7.14  | 20.00 | 22    |
| N06AA09 | Amitriptyline                       | 22.06  | 16.90  | 14.29  | 3.57  | 10.00 | 17    |
| C07AB07 | Bisoprolol                          | 15.73  | 10.19  | 10.20  | 3.57  | 15    |
| C07AA05 | Propranolol                         | 6.82   | 4.17   | 4.08   | 14.29 | 30.00 | 17    |
| C07AB02 | Metoprolol                          | 4.91   | 4.86   | 5.10   | 7.14  | 6     |
| N06CA01 | Amitriptyline and psycholeptics     | 4.68   | 3.47   | 4.08   | 7.14  | 50.00 | 47    |
| N03AX11 | Topiramate                          | 3.73   | 8.10   | 7.14   | 7.14  | 20.00 | 100   | 41    |
| N06AA10 | Nortriptyline                       | 3.55   | 6.25   | 4.08   | 7.14  | 42    |
| C07AB12 | Nebivolol                           | 1.68   | 2.78   | 1.02   | 3.57  | 22    |
| M03AX01 | Botulinum toxin                     | 1.05   | 3.70   | 11.22  | 7.14  | 10.00 | 64    |
| C08DA01 | Verapamil                           | 1.05   | 1.62   | 3.57   | 23    |
| N03AX09 | Lamotrigine                         | 0.86   | 0.93   | 3.06   | 50    |
| N03AG01 | Valproic acid                       | 0.82   | 3.70   | 1.02   | 7.14  | 50.00 | 58    |
| C09CA01 | Losartan                            | 0.82   | 1.62   | 1.02   | 4     |
| C09CA08 | Olmesartan medoxomil                | 0.64   | 1.16   | 1.02   | 80    |
| N03AX12 | Gabapentin                          | 0.50   | 1.16   | 2.04   | 56    |
| C09CA07 | Telmisartan                         | 0.45   | 0.23   | 9      |
| G03CA03 | Estradiol                           | 0.36   | 0.23   | 0      |
| N06AA12 | Doxepin                             | 0.32   | 0.69   | 3.57   | 64    |
| N03AX16 | Pregabalin                          | 0.27   | 0.69   | 11     |
| C07AB03 | Atenolol                            | 0.23   |       | 40     |
| N06AA06 | Trimipramine                        | 0.18   | 0.23   | 1.02   | 67    |
| G03AC09 | Desogestrel                         | 0.18   | 0.23   | 3.57   | 0     |
| N06AX21 | Duloxetine                          | 0.14   | 0.69   | 1.02   | 29    |
| N06AX16 | Venlafaxine                         | 0.14   | 0.23   | 3.57   | 100   |
| G02BA03 | Plastic IUD with progestogen        | 0.14   | 1.02   | 3.57   | 10.00 |
| C09DA06 | Candesartan and diuretic            | 0.09   | 0.23   | 3.57   | 0     |
| C08CA06 | Nimodipine                          | 0.09   | 0.23   | 100    |
| C08CA05 | Nifedipine                          | 0.09   | 1.02   | 3.57   | 0     |
| C08CA01 | Amlodipine                          | 0.09   |       | 0      |
| C07BB07 | Bisoprolol and thiazides            | 0.09   |       | 50     |
| N06AB10 | Escitalopram                        | 0.09   |       | 0      |
| G03AA12 | Drospirenone ja ethinylestradiol    | 0.05   | 0.69   | 0      |
| C08DB01 | Diltiazem                           | 0.05   | 0.23   | 0      |
| G03HB01 | Cyproterone and estrogen            | 0.05   | 0.23   | 0      |
| N03AE01 | Clonazepam                          | 0.05   | 1.02   | 50     |
| C07AB05 | Betaxolol                           | 0.05   |       | 0      |
| C07AA03 | Pindolol                            | 0.05   |       | 0      |
| N06AX11 | Mirtazapine                         | 0.05   |       | 0      |
| N06AX22 | Agomelatine                         | 0.05   |       | 0      |
| G03AA14 | Nomegestrol and estradiol           | 0.05   |       | 0      |
| N06AB03 | Fluoxetine                          | 0.05   |       | 0      |
| C09AA05 | Ramipril                            | 0.05   |       | 100    |
Table 3 Prophylactic treatment lines of patients with G43*diagnosis and the word migraine in the free text of a prophylactic migraine prescription. A new treatment line was defined as a new drug prescription (Continued)

| ATC    | Drug name                                      | 1 (%) | 2 (%) | 3 (%) | 4 (%) | 5 (%) | 6 (%) | 7 (%) | Prescr. by neurologist (%) |
|--------|------------------------------------------------|-------|-------|-------|-------|-------|-------|-------|----------------------------|
| C09BX01 | Perindopril, amlodipine and indapamide         | 0.05  | 432   | 98    | 28    | 10    | 2     | 1     | 0                          |
| C07BB02 | Metoprolol and thiazides                       | 0.05  | 0     |       |       |       |       |       | 0                          |
| N03AF02 | Oxcarbazepine                                  | 0.05  | 0     |       |       |       |       |       | 0                          |
| G03BA03 | Testosterone                                   | 0.05  | 0     |       |       |       |       |       | 0                          |
| C07AA07 | Sotalol                                        | 0.05  | 100   |       |       |       |       |       |                            |
| G02BB01 | Vaginal ring with progestogen and estrogen      | 0.05  | 0     |       |       |       |       |       | 0                          |
### Appendix 2

**Table 4** Acute migraine prescription frequency on the G43* population, the list includes acute medication from both acute and prophylactic groups (N = 8244)

| ATC Medication | Group Description | N     | Proportion of patients (%) |
|----------------|-------------------|-------|-----------------------------|
| N02CC01 Sumatriptan | Selective serotonin (SHT1) agonists | 3962  | 48.06%                      |
| M01AE02 Naproxen | Antiinflammatory and antirheumatic products | 1698  | 20.60%                      |
| N02CC07 Frovatriptan | Selective serotonin (SHT1) agonists | 1227  | 14.88%                      |
| N02CC04 Ritisatriptan | Selective serotonin (SHT1) agonists | 989   | 12.00%                      |
| M01AE01 Ibuprofen | Antiinflammatory and antirheumatic products | 889   | 10.78%                      |
| N02CC03 Zolmitriptan | Selective serotonin (SHT1) agonists | 763   | 9.26%                       |
| N02CC06 Etofylline | Selective serotonin (SHT1) agonists | 673   | 8.16%                       |
| A03FA01 Metoclopramide | Propulsives | 664   | 8.05%                       |
| N02CC05 Almotriptan | Selective serotonin (SHT1) agonists | 566   | 6.87%                       |
| M01AG02 Tolfenamic acid | Antiinflammatory and antirheumatic products | 530   | 6.43%                       |
| N02BE01 Paracetamol | Antiinflammatory and antirheumatic products | 391   | 4.74%                       |
| M01AE03 Ketoprofen | Antiinflammatory and antirheumatic products | 192   | 2.33%                       |
| N02AA59 Codeine combinations | Opioids | 178   | 2.16%                       |
| M01AB05 Diclofenac | Antiinflammatory and antirheumatic products | 165   | 2.00%                       |
| N02CC02 Naratriptan | Antiinflammatory and antirheumatic products | 107   | 1.30%                       |
| H02AB06 Prednisolone | Corticosteroids for systemic use, plain | 95    | 1.15%                       |
| M01AE17 Dexamethasone | Antiinflammatory and antirheumatic products | 70    | 0.85%                       |
| N02AO06 Codeine and paracetamol | Opioids | 61    | 0.74%                       |
| H02AB04 Methylprednisolone | Corticosteroids for systemic use, plain | 48    | 0.58%                       |
| N02BA01 Acetylsalicylic acid | Other analgesics and antipyretics | 43    | 0.52%                       |
| M01AB01 Indomethacin | Antiinflammatory and antirheumatic products | 38    | 0.46%                       |
| M03BC51 Ofenadrine combinations | Muscle relaxants, centrally acting agents | 38    | 0.46%                       |
| M01AH05 Etoricoxib | Antiinflammatory and antirheumatic products | 26    | 0.32%                       |
| M03BX02 Tizanidine | Muscle relaxants, centrally acting agents | 24    | 0.29%                       |
| M01AG01 Mefenamic acid | Antiinflammatory and antirheumatic products | 21    | 0.25%                       |
| A04AA01 Ondansetron | Serotonin (SHT3) antagonists | 16    | 0.19%                       |
| H02AB07 Prednisone | Corticosteroids for systemic use, plain | 14    | 0.17%                       |
| N02AX02 Tramadol | Opioids | 14    | 0.17%                       |
| H02AB01 Dexametasone | Corticosteroids for systemic use, plain | 13    | 0.16%                       |
| M01AE52 Naproxen and Esomeprazole | Antiinflammatory and antirheumatic products | 12    | 0.15%                       |
| A03DA02 Pitofenone and Analgesics | Synthetic anticholinergic agents in combination with analgesics | 8     | 0.10%                       |
| M01AC06 Meloxicam | Antiinflammatory and antirheumatic products | 5     | 0.06%                       |
| M03 BC01 Orfenadrine | Muscle relaxants, centrally acting agents | 5     | 0.06%                       |
| N02AJ08 Codeine and ibuprofen | Opioids in combination with non-opioid analgesics | 4     | 0.05%                       |
| M01AH01 Celecoxib | Antiinflammatory and antirheumatic products | 3     | 0.04%                       |
| N02BE51 Paracetamol combinations | Antiinflammatory and antirheumatic products | 3     | 0.04%                       |
| M01AB08 Etodolac | Antiinflammatory and antirheumatic products | 1     | 0.01%                       |
| M01AX01 Nabumetone | Antiinflammatory and antirheumatic products | 1     | 0.01%                       |
| M03BX01 Baclofen | Muscle relaxants, centrally acting agents | 1     | 0.01%                       |
| N02AX52 Tramadol combinations | Opioids in combination | 1     | 0.01%                       |
| N02BA51 Acetylsalicylic acid, combinations | Other analgesics and antipyretics | 1     | 0.01%                       |
### Table 5: The frequency (%) of comorbidities in controls and patients of the primary cohort

| Major depressive disorder, single episode | Major depressive disorder, recurrent | Other anxiety disorders | Reaction to severe stress, and adjustment disorders | Sleep disorders not due to a substance or known physiological condition | Acute sinusitis | Acute upper respiratory infections of multiple and unspecified sites | Acute bronchitis | Other and unspecified dorsiopathies, not elsewhere classified | Dorsalgia |
|-----------------------------------------|------------------------------------|------------------------|---------------------------------------------------|-------------------------------------------------|----------------|-------------------------------------------------|----------------|-------------------------------------------------|---------|
| F32 | F33 | F41 | F43 | F51 | J01 | J06 | J20 | M53 | M54 |
| Cohort | Control | 7.1 | 2.5 | 7.9 | 99 | 88 | 25.2 | 52.2 | 17.9 | 14.3 | 31.4 |
| G43* primary cohort | 13.0 | 4.8 | 14.1 | 17.4 | 174 | 38.0 | 71.7 | 26.0 | 28.6 | 468 |
| p-value | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| Primary cohort subgroups | No prescription | 12.4 | 5.0 | 13.5 | 17.5 | 167 | 36.2 | 71.7 | 25.6 | 27.1 | 463 |
| Acute prescriptions | 12.5 | 4.2 | 13.7 | 16.8 | 17.1 | 39.2 | 72.1 | 26.1 | 28.4 | 467 |
| Prophylactic prescription | 17.1 | 5.9 | 17.5 | 18.8 | 206 | 41.2 | 704 | 27.3 | 35.6 | 491 |
| p-value | < 0.001 | 0.002 | < 0.001 | 0.091 | < 0.001 | < 0.001 | 0.242 | < 0.001 | 0.058 |
| Prophylactic treatment line | 0 | 12.4 | 4.6 | 13.6 | 17.2 | 169 | 37.5 | 71.8 | 25.8 | 27.6 | 465 |
| 1 | 16.2 | 5.7 | 16.6 | 18.3 | 203 | 39.9 | 696 | 26.6 | 34.2 | 487 |
| 2 | 18.0 | 5.7 | 18.9 | 21.0 | 201 | 44.9 | 728 | 29.9 | 40.1 | 527 |
| ≥3 | 30.6 | 10.2 | 28.6 | 21.4 | 276 | 52.0 | 765 | 31.6 | 44.9 | 551 |
| p-value | < 0.001 | < 0.001 | < 0.001 | 0.138 | < 0.001 | < 0.001 | 0.155 | < 0.001 | < 0.001 | < 0.001 |
| Botulinum toxin prescription | no | 12.9 | 4.8 | 14.0 | 17.4 | 174 | 37.9 | 71.7 | 26.0 | 28.6 | 468 |
| yes | 32.1 | 9.4 | 28.3 | 22.6 | 15.1 | 54.7 | 736 | 43.4 | 52.8 | 566 |
| p-value | < 0.001 | 0.112 | 0.003 | 0.312 | 0.662 | 0.012 | 0.755 | 0.004 | < 0.001 | 0.152 |
### Appendix 4

#### Table 6
Overall visits per patient-year of the primary cohort stratified by quartiles

| Visits (overall) | q1     | q2         | q3         | q4     | \( p \)-value* |
|------------------|--------|------------|------------|--------|----------------|
| Cut-off (visits per patient-year) | < 7.03 | 7.03–12.22 | 12.23–19.79 | > 19.79 | --             |
| Follow-up time, years (median)     | 3.25   | 3.35       | 3.18       | 2.64   | < 0.001        |
| N                              | 3990   | 3992       | 3991       | 3991   | --             |
| Female (%)                     | 73.7%  | 77.1%      | 81.5%      | 85.9%  | < 0.001        |
| Age, years (mean)              | 36.06  | 39.07      | 40.14      | 40.75  | < 0.001        |
| Acute prescription only, %     | 34.1%  | 34.5%      | 38.2%      | 38.8%  | < 0.001        |
| No prescription, %             | 58.6%  | 54.0%      | 48.6%      | 41.9%  |                |
| Prophylactic prescription, %   | 7.3%   | 11.5%      | 13.2%      | 19.3%  |                |
| Botulinum toxin A, %           | 0.1%   | 0.1%       | 0.3%       | 0.9%   | < 0.001        |
| Prophylactic treatment line 0   | 92.68% | 88.53%     | 86.82%     | 80.68% | < 0.001        |
| 1                             | 6.64%  | 9.17%      | 10.52%     | 14.48% |               |
| 2                             | 0.65%  | 2.00%      | 2.08%      | 3.36%  |               |
| \( \geq 3 \)                  | 0.03%  | 0.30%      | 0.58%      | 1.48%  |               |

*\( p \)-value for test for all quartiles equal

### Appendix 5

#### Table 7
Overall sick leave days per patient-year of the primary cohort stratified by quartiles

| Sick leave days (overall) | q1     | q2         | q3         | q4     | \( p \)-value* |
|--------------------------|--------|------------|------------|--------|----------------|
| Cut-off (sick leave days per patient-year) | < 1.92 | 1.93–7.09  | 7.10–19.85 | > 19.85 | --             |
| Follow-up time, years (median)     | 2.84   | 3.28       | 3.30       | 3.06   | < 0.001        |
| N                              | 3990   | 3992       | 3991       | 3991   | --             |
| Female, (%)                   | 73.0%  | 79.3%      | 81.5%      | 82.5%  | < 0.001        |
| Age, years (mean)             | 39.9   | 38.4       | 38.2       | 39.5   | < 0.001        |
| Acute prescription only, %     | 36.3%  | 36.5%      | 36.1%      | 36.6%  | < 0.001        |
| No prescription, %            | 53.1%  | 51.6%      | 50.8%      | 47.7%  |                |
| Prophylactic prescription, %   | 10.7%  | 11.9%      | 13.1%      | 15.7%  |                |
| Botulinum toxin A, %          | 0.2%   | 0.1%       | 0.3%       | 0.7%   | < 0.001        |
| Prophylactic treatment line 0  | 89.3%  | 88.1%      | 86.9%      | 84.3%  | < 0.001        |
| 1                             | 9.1%   | 9.6%       | 10.2%      | 11.9%  |               |
| 2                             | 1.3%   | 2.0%       | 2.0%       | 2.8%   |               |
| \( \geq 3 \)                  | 0.3%   | 0.3%       | 0.8%       | 1.0%   |               |

*\( p \)-value for test for all quartiles equal
Abbreviations
CM: Chronic migraine; EM: Episodic migraine; EMR: Electronic medical records; HCRU: Health care resource utilization

Acknowledgements
The authors wish to thank all co-workers at Novartis, Medaffcon and Terveys- talo who have shared their knowledge and support making the study possible.

Funding
The study was funded by Novartis Finland.

Availability of data and materials
Suomen Terveystalo Plc. authorities are responsible for administrative decisions controlling access to EMR data and ensuring data privacy according the Finnish laws.

Authors’ contributions
MAK: contributed to study conception and interpretation of data, was involved in manuscript writing and revision, gave final approval for manuscript for publication, agreed to be accountable for all aspects of the work. MC-S: contributed to study conception and interpretation of data, was involved in manuscript revision, gave final approval for manuscript for publication, agreed to be accountable for all aspects of the work. TP: contributed to study conception and interpretation of data, was involved in manuscript writing and revision, gave final approval for manuscript for publication, agreed to be accountable for all aspects of the work. SK: contributed to data acquisition and interpretation of data, was involved in manuscript revision, gave final approval for manuscript for publication, agreed to be accountable for all aspects of the work. MN: contributed to data acquisition and interpretation of data, was involved in manuscript revision, gave final approval for manuscript for publication, agreed to be accountable for all aspects of the work. IT: contributed to data acquisition and interpretation of data, was involved in manuscript writing and revision, gave final approval for manuscript for publication, agreed to be accountable for all aspects of the work. CM: contributed to data acquisition and interpretation of data, was involved in manuscript writing and revision, gave final approval for manuscript for publication, agreed to be accountable for all aspects of the work. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1211–1259
3. Serrano D, Lipton RB, Scher AI, Reed ML, Adams AM, Buse D (2017) Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain 18:101. https://doi.org/10.1186/s10194-017-0787-1
4. Sillangää M, Andlin-Sobocki P, Lonnqvist J (2008) Costs of brain disorders in Finland. Acta Neurolog Scand 117:167–172
5. Martelletti P, Schwedt TJ, Lanteri-Minet M, Quintana R, Carboni V, Diener HC, Ruiz de la Torre E, Craven A, Rasmussen AV, Evans S, Lafframme AK, Fink R, Walsh D, Dumas P, Vo P (2018) My migraine voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 19:115. https://doi.org/10.1186/s10194-018-0946-z
6. Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, Lipton RB (2012) Chronic migraine prevalence, disability, and sociodemographic factors: results from the American migraine prevalence and prevention study. Headache 52:1456–1470
7. Payne KA, Varon SF, Kawata AK, Yocmans K, Wilcox TK, Manack A, Buse DC, Lipton RB, Goadsby PJ, Blumenfeld AM (2011) The international burden of migraine study (IBMS): study design, methodology, and baseline cohort characteristics. Cephalalgia 31:1116–1130
8. Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, Varon SF, Blumenfeld AM, Katsarava Z, Fischl J, Lanteri-Minet M, Cortelli P, Martelletti P (2012) Cost of healthcare for patients with migraine in five European countries: results from the international burden of migraine study (IBMS). J Headache Pain 13:361–378
9. Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, Goadsby PJ, Lipton RB (2011) Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the international burden of migraine study. Cephalalgia 31:301–305
10. Adams AM, Serrano D, Buse DC, Reed ML, Manske V, Fanning KM, Lipton RB (2015) The Impact of chronic migraine: the chronic migraine epidemiology and outcomes (CaMEO) study methods and baseline results. Cephalalgia 35:563–578
11. Andrée C, Stovner LJ, Baré J, Katsarava Z, Lainez JM, Lanteri-Minet M, Mick G, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Vriezen P, Lampl C (2011) The Eurolight project: the impact of primary headache disorders in Europe. Description of methods. J Headache Pain 12:541–549
12. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388:1545–1602
13. Silberstein SD, Lee L, Gandhi K, Fitzgerald T, Bell J, Cohen JM (2018) Health care resource utilization and migraine disability along the migraine care continuum among patients treated for migraine. Headache 58:1579–1592. https://doi.org/10.1111/head.13421
14. Katsarava Z, Buse DC, Manack AN, Lipton RB (2012) Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep 16:86–92
15. Burshtin R, Burshtin J, Rosen N (2015) Are episodic and chronic migraine one disease or two? Curr Pain Headache Rep 19:53. https://doi.org/10.1007/s11916-015-0529-5
16. Silberstein SD, Dodick D, Freitag F, Pearlman SH, Hahn SR, Scher AI, Lipton RB (2007) Pharmacological approaches to managing migraine and associated comorbidities—clinical considerations for monotherapy versus polytherapy. Headache 47:585–599
17. Minen MT, De Dhaem OB, Van Diest AK, Powers S, Schwedt TJ, Lipton R, Silberstein D (2016) Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry 87:741–749
18. Pesa J, Lage MJ (2004) The medical costs of migraine and comorbid anxiety and depression. Headache 44:562–570
19. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B, CBDe2010 Study Group, & European Brain Council (2012) The economic cost of brain disorders in Europe. Eur J Neurol 19:155–162
20. Migraine. Current Care Guidelines. Working group set up by the Finnish Medical Society Duodecim and the Finnish Neurological Society. Helsinki: The Finnish Medical Society Duodecim, 2015 (referred September 30, 2018). Available online at: www.kaypahoito.fi.
21. Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 20:22–33
22. Ford JH, Jackson J, Milligan G, Cotton S, Ahl J, Aurora SK (2017) A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns. Headache 57:1532–1544

23. Ford JH, Schroeder K, Nyhus AW, Foster SA, Aurora SK (2018) Cycling through migraine preventive treatments: implications for all-cause total direct costs and disease-specific costs. J Manag Care Spec Pharm 25:1–12. https://doi.org/10.18553/jmcp.2018.18058.

24. Honkasalo ML, Kaprio J, Heikkinä K, Sillanpää M, Koskenvuo M (1993) A population-based survey of headache and migraine in 22,809 adults. Headache 33:403–412

25. Raggi A, Leonardi M (2015) Burden and cost of neurological diseases: a European north–south comparison. Acta Neurol Scand 132:16–22

26. Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, Lainez JM, Lamp C, Lantéri-Minet M, Rastenyte D (2012) The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 19:703–711

27. Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MFT, Tierce J, Reed M, Lipton RB (2009) Economic burden of transformed migraine: results from the American migraine prevalence and prevention (AMPP) study. Headache 49:498–508

28. Juang KD, Wang SJ, Fuh JL, Lu SR, Su TP (2000) Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes. Headache 40:818–823

29. Wu J, Davis-Ajami ML, Kevin LZ (2016) Impact of depression on health and medical care utilization and expenses in US adults with migraine: a retrospective cross sectional study. Headache 56:1147–1160

30. Wang SJ, Fuh JL, Chen PK (2010) Comorbidities of migraine. Front Neurol 1:1. https://doi.org/10.3389/fneur.2010.00016

31. Fernández-de-las-Peñas C, Fernández-Muñoz JJ, Palacios-Ceña M, Parás-Bravo P, Cigarrán-Méndez M, Navarro-Pardo E (2018) Sleep disturbances in tension-type headache and migraine. Ther Adv Neurol Disord 11:1–6

32. D'Amico D, Sansone E, Grazzi L, Giovannetti AM, Leonardi M, Schiavolin S, Raggi A (2018) Multimorbidity in patients with chronic migraine and medication overuse headache. Acta Neurol Scand. E-published ahead of print 14 Aug 2018. https://doi.org/10.1111/ane.13014

33. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, AMPP Advisory Group (2017) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343–349

34. Radtke A, Neuhauser H (2012) Low rate of self-awareness and medical recognition of migraine in Germany. Cephalalgia 32:1023–1030

35. Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton RB, Scher AI, Steiner TJ, Zwart J-A (2007) The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27:193–210

36. Vetvik KG, MacGregor EA (2017) Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol 16:76–87

37. Violán C, Foguet-Boreu Q, Hermosilla-Pérez E, Valderas JM, Ballesteros-Fernández de las Peñas M, Muñoz-Pérez MA (2013) Comparison of the information provided by electronic health records data and a population health survey to estimate prevalence of selected health conditions and multimorbidity. BMC Public Health 13:251. https://doi.org/10.1186/1471-2458-13-251

38. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB (2007) Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American migraine prevalence and prevention study. Headache 47:355–363

39. Tepper SJ, Dahlöf CG, Dowson A, Newman L, Mansbach H, Jones M, Pham B, Webster C, Salonen R (2004) Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the landmark study. Headache 44:856–864

40. Katsarava Z, Mania M, Lamp C, Herberhold J, Steiner TJ (2018) Poor medical care for people with migraine in Europe - evidence from the Eurolight study. J Headache Pain 19:10. https://doi.org/10.1186/s10194-018-0839-1

41. Boudreau GP, Grosberg BM, McAllister PJ, Lipton RB, Buse DC (2015) Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: an open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety. Int J Gen Med 8:79